An unusual case of checkpoint-inhibitor-induced pleuropericarditis.
| Autor: | Suarez ZK; Internal Medicine Department, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, USA., Finke AC; Internal Medicine Department, Universidad Iberoamericana, Santo Domingo, Dominican Republic., Hospedales E; Internal Medicine Department, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, USA., Perez E; Internal Medicine Department, Kendall Regional Medical Center, Kendall, FL, USA., Sharifzadeh A; Internal Medicine Department, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, USA., Foster J; Internal Medicine Department, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, USA., Ferris A; Internal Medicine Department, Florida Atlantic University Charles E. Schmidt College of Medicine, Boca Raton, FL, USA. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners [J Oncol Pharm Pract] 2023 Sep; Vol. 29 (6), pp. 1525-1528. Date of Electronic Publication: 2023 May 30. |
| DOI: | 10.1177/10781552231179369 |
| Abstrakt: | Introduction: Pembrolizumab is an immune checkpoint inhibitor that promotes effector T-cell functions on malignant cells by binding to programmed cell death protein 1 (PD-1). Pembrolizumab is well tolerated in most cases with an adverse event profile consisting mainly of pruritus, fatigue, and anorexia. Cardiotoxicity comprises 1% of the total adverse events. Case Report: We present a case of a 64-year-old female with non-small cell lung cancer (NSCLC) who developed pleuropericarditis following pembrolizumab therapy. Management & Outcome: The patient was successfully managed with colchicine, furosemide, and timely initiation of methylprednisolone with the improvement of her symptoms. The decision to discontinue pembrolizumab was made, and six months after this intervention, the patient has remained asymptomatic. Discussion: Clinicians should recognize these potential immune-mediated adverse effects to provide effective and timely management and optimize patient care. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|